Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 8/20 | 0.37 |
| ▸ | PDE3A | Q14432 | 8/20 | 0.37 |
| ▸ | CMA1 | P23946 | 6/20 | 0.33 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.33 |
| ▸ | MDM4 | O15151 | 2/20 | 0.33 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13316635 | 0.89 | PDE3B (0.36) | PDE3BPDE3ACMA1MDM4MDM2 | |
| SCHEMBL3627969 | 0.82 | PDE3B (0.41) | PDE3BPDE3ACMA1KDM4EALDH1A1 | |
| SCHEMBL3620368 | 0.82 | PDE3B (0.43) | PDE3BPDE3ACMA1KDM4EALDH1A1 | |
| SCHEMBL13316622 | 0.80 | PDE3B (0.41) | PDE3BPDE3ACMA1KDM4EALDH1A1 | |
| SCHEMBL13316644 | 0.79 | PDE3B (0.41) | PDE3BPDE3ACMA1KDM4EALDH1A1 | |
| SCHEMBL13316642 | 0.79 | PDE3B (0.38) | PDE3BPDE3ACMA1KDM4EALDH1A1 | |
| SCHEMBL13316621 | 0.79 | PDE3B (0.40) | PDE3BPDE3ACMA1KDM4EALDH1A1 | |
| SCHEMBL13316646 | 0.77 | CFD (0.37) | PDE3BPDE3ATP53KDM4EALDH1A1 | |
| SCHEMBL13316648 | 0.77 | PDE3B (0.38) | PDE3BPDE3ATP53KDM4EALDH1A1 | |
| SCHEMBL13316657 | 0.76 | MRGPRX4 (0.39) | PDE3BPDE3ACMA1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7745459-B2 | Quinolizinone compound and use thereof as HIV integrase inhibitor | JAPAN TOBACCO INC. (JP) | 2010-06-29 | — | — | US | disclosed |
| US-7745459-B2 | Quinolizinone compound and use thereof as HIV integrase inhibitor | JAPAN TOBACCO INC. (JP) | 2010-06-29 | — | — | US | disclosed |
| US-7745459-B2 | Quinolizinone compound and use thereof as HIV integrase inhibitor | JAPAN TOBACCO INC. (JP) | 2010-06-29 | — | — | US | disclosed |
| US-20060084665-A1 | Quinolizinone compound and use thereof as HIV integrase inhibitor | JAPAN TOBACCO INC. (JP) | 2006-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084665-A1 | Quinolizinone compound and use thereof as HIV integrase inhibitor | NQO2, ACE, CDK20 | PDE3B 616/4885PDE3A 694/4885CMA1 738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.